Author:
Lv Mu,Chen Peiqin,Bai Mingzhu,Huang Yan,Li Linxia,Feng Youji,Liao Hong,Zheng Wenxin,Chen Xiaojun,Zhang Zhenbo
Abstract
With a younger tendency in morbidity age, endometrial cancer (EC) incidence has grown year after year. Worse, even more commonly occurring is endometrial hyperplasia (EH), which is a precancerous endometrial proliferation. For young women with early EC and EH who want to preserve fertility, progestin therapy has been utilized as a routine fertility-preserving treatment approach. Nevertheless, progestin medication failure in some patients is mostly due to progestin resistance and side effects. In order to further analyze the potential mechanisms of progestin resistance in EH and EC, to provide theoretical support for effective therapeutic strategies, and to lay the groundwork for searching novel treatment approaches, this article reviews the current therapeutic effects of progestin in EH and EC, as well as the mechanisms and molecular biomarkers of progestin resistance, and systematically expounds on the potential therapeutic methods to overcome progestin resistance.
Funder
National Natural Science Foundation of China
National Key Technology R&D Program of China
Shanghai Municipal Science and Technology Committee of Shanghai outstanding academic leaders plan
project of Outstanding Medical Doctor for ZZ, Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support
Shanghai Talent Development Foundation
Shanghai Municipal Science and Technology Committee of Multi-center Clinical Study Project
Shanghai Collaborative Innovation Center of Translational Medicine
Shanghai Songjiang Leading Talent Program
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献